Oncopeptides AB(SE:ONCO)
kr 1.77+0.00 (+0.06%)
SE:ONCO
Oncopeptides AB stock drug pipeline
kr 1.77
At close:+0.00 (+0.06%)
Want to see SE:ONCO full AI Analyst Report?
Oncopeptides AB (ONCO) Drug Pipeline
11 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Opd5 | Multiple Myeloma, Relapse Multiple Myeloma | Phase I | Withdrawn | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma | May 27, 2021 | ― |
| Dexamethasone, Daratumumab, Melflufen | Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase III | Terminated | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma | Nov 24, 2020 | ― |
| Dexamethasone, Melphalan | Rrmm | Phase II | Terminated | A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients | May 18, 2020 | ― |
| Dexamethasone, Melphalan-Flufenamide (Melflufen) | Al Amyloidosis | Phase I | Terminated | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | Aug 29, 2019 | ― |
| Dexamethasone, Melflufen | Multiple Myeloma, Renal Impairment | Phase II | Terminated | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function | Aug 14, 2018 | ― |
| Dexamethasone, Daratumumab, Bortezomib, Melphalan Flufenamide (Melflufen) | Multiple Myeloma | phase1AndPhase2 | Terminated | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | Mar 06, 2018 | ― |
| Dexamethasone, Pomalidomide, Melflufen | Multiple Myeloma | Phase III | Terminated | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide | May 09, 2017 | ― |
| Dexamethasone, Melphalan Flufenamide (Melflufen) | Multiple Myeloma | Phase II | Completed | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Oct 18, 2016 | ― |
| Dexamethasone, Melflufen | Relapsed And/Or Relapsed-Refractory Multiple Myeloma | phase1AndPhase2 | Terminated | Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients | Jul 09, 2013 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Opd5 | Phase I | Multiple Myeloma, Relapse Multiple Myeloma | Withdrawn | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma | May 27, 2021 | ― |
| Dexamethasone, Daratumumab, Melflufen | Phase III | Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Terminated | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma | Nov 24, 2020 | ― |
| Dexamethasone, Melphalan | Phase II | Rrmm | Terminated | A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients | May 18, 2020 | ― |
| Dexamethasone, Melphalan-Flufenamide (Melflufen) | Phase I | Al Amyloidosis | Terminated | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | Aug 29, 2019 | ― |
| Dexamethasone, Melflufen | Phase II | Multiple Myeloma, Renal Impairment | Terminated | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function | Aug 14, 2018 | ― |
| Dexamethasone, Daratumumab, Bortezomib, Melphalan Flufenamide (Melflufen) | phase1AndPhase2 | Multiple Myeloma | Terminated | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | Mar 06, 2018 | ― |
| Dexamethasone, Pomalidomide, Melflufen | Phase III | Multiple Myeloma | Terminated | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide | May 09, 2017 | ― |
| Dexamethasone, Melphalan Flufenamide (Melflufen) | Phase II | Multiple Myeloma | Completed | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Oct 18, 2016 | ― |
| Dexamethasone, Melflufen | phase1AndPhase2 | Relapsed And/Or Relapsed-Refractory Multiple Myeloma | Terminated | Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients | Jul 09, 2013 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oncopeptides AB (SE:ONCO) have in its pipeline
Oncopeptides AB SE:ONCO is currently developing the following drugs: Opd5, Dexamethasone, Daratumumab, Melflufen, Dexamethasone, Melphalan, Dexamethasone, Melphalan-Flufenamide (Melflufen), Dexamethasone, Melflufen, Dexamethasone, Daratumumab, Bortezomib, Melphalan Flufenamide (Melflufen), Dexamethasone, Pomalidomide, Melflufen, Dexamethasone, Melphalan Flufenamide (Melflufen). These drug candidates are in various stages of clinical development as the company works toward FDA approval.

